---
schema_version: "secwatch.filing_event.v1"
accession: "0001200375-23-000009"
form_type: "8-K"
ticker: "CDXS"
cik: "0001200375"
company_name: "CODEXIS, INC."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T01:39:49.290523+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Codexis reports FY2022 revenue $138.6M (+32% YoY); net loss $33.6M; provides 2023 guidance $63-68M ex-PAXLOVID

## Summary
- FY2022 total revenue $138.6M (+32% YoY); ex-PAXLOVID revenue $63.2M (-10% YoY). Net loss $33.6M ($0.51/share) vs $21.3M loss in 2021.
- Q4 2022 revenue $30.4M (+24% YoY); net loss $12.6M ($0.19/share) vs $10.2M loss in Q4 2021.
- 2023 guidance: total revenue $63-68M, product revenue $35-40M (both ex-PAXLOVID); gross margin 68-73%. Cash runway through end 2024.
- Roche exercised ROFN on newly engineered DNA ligase for NGS; interim Phase 1 data for CDX-7108 (EPI) with Nestlé showed improved lipid absorption.
- Upcoming IND filings: Nestlé for PKU (CDX-6114) H2 2023; Nestlé for EPI (CDX-7108) by end 2023; Takeda for Fabry as soon as late 2023.

## SEC filing metadata
- accession: 0001200375-23-000009
- form_type: 8-K
- ticker: CDXS
- cik: 0001200375
- company_name: CODEXIS, INC.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1200375/000120037523000009/0001200375-23-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1200375/000120037523000009/cdxs-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001200375-23-000009
- JSON: https://secwatch.observer/filing/0001200375-23-000009.json
- Plain text: https://secwatch.observer/filing/0001200375-23-000009.txt

## Key facts
- Earnings Releases
  CODEXIS, INC. reported financial results for the fourth quarter ended December 31, 2022.
  - Period: the fourth quarter ended December 31, 2022
  - Result: reported results
  source text: On February 23, 2023, Codexis, Inc. (the “Company”) announced its financial results for the fourth quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1200375/000120037523000009/0001200375-23-000009-index.htm
- Earnings Releases
  CODEXIS, INC. reported the fiscal year ended December 31, 2022 results: revenue $138.6 million.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: $138.6 million
  - Result: reported results
  source text: Total revenues for fiscal year 2022 were $138.6 million, an increase of 32% from $104.8 million the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1200375/000120037523000009/0001200375-23-000009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.